Andrew X. Zhu
Harvard University
529 Papers
4.2K Citations
Andrew X. Zhu is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 89, co-authored 489 publications. Previous affiliations of Andrew X. Zhu include Fudan University & Beth Israel Deaconess Medical Center.
Chat about Author
Papers
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu,Dushyant V. Sahani,Dan G. Duda,Emmanuelle di Tomaso,Marek Ancukiewicz,Onofrio A. Catalano,Vivek Sindhwani,Lawrence S. Blaszkowsky,Sam S. Yoon,Johanna Lahdenranta,Pankaj Bhargava,Jeffrey A. Meyerhardt,Jeffrey W. Clark,Eunice L. Kwak,Aram F. Hezel,Rebecca A. Miksad,Thomas A. Abrams,Peter C. Enzinger,Charles S. Fuchs,David P. Ryan,Rakesh K. Jain +20 more
TL;DR: Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects and Rapid changes in tumor vascular permeability and circulating inflammatory biomarkers are potential determinants of response and resistance to sunitinIB in HCC.
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Lipika Goyal,Supriya K. Saha,Leah Y. Liu,Giulia Siravegna,Ignaty Leshchiner,Leanne G. Ahronian,Jochen K. Lennerz,Phuong Vu,Vikram Deshpande,Avinash Kambadakone,Benedetta Mussolin,Stephanie Reyes,L. Henderson,Jiaoyuan Elisabeth Sun,Emily E. Van Seventer,Joseph M. Gurski,Sabrina Baltschukat,Barbara Schacher-Engstler,Louise Barys,Christelle Stamm,Pascal Furet,David P. Ryan,James R. Stone,A. John Iafrate,Gad Getz,Gad Getz,Diana Graus Porta,Ralph Tiedt,Alberto Bardelli,Dejan Juric,Ryan B. Corcoran,Nabeel Bardeesy,Andrew X. Zhu +32 more
TL;DR: The first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC are reported, which can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target.
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.
Peter R. Galle,Friedrich Foerster,Masatoshi Kudo,Stephen L. Chan,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Shukui Qin,William R. Schelman,Sudhakar Chintharlapalli,Paolo Abada,Morris Sherman,Andrew X. Zhu +12 more
TL;DR: Data demonstrate the relevance of alpha‐fetoprotein for patients with HCC and identify several remaining questions that will benefit from future research.
455
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Aparna Raj Parikh,Ignaty Leshchiner,Liudmila Elagina,Lipika Goyal,Chaya Levovitz,Giulia Siravegna,Dimitri Livitz,Kahn Rhrissorrakrai,Elizabeth E. Martin,Emily E. Van Seventer,Megan Hanna,Kara Slowik,Filippo Utro,Christopher J. Pinto,Alicia Wong,Brian P. Danysh,Ferran Fece de la Cruz,Isobel J Fetter,Brandon Nadres,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Bruce J. Giantonio,Janet E. Murphy,Ryan D. Nipp,Eric Roeland,David P. Ryan,Colin D. Weekes,Eunice L. Kwak,Jason E. Faris,Jennifer Y. Wo,François Aguet,Ipsita Dey-Guha,Mehlika Hazar-Rethinam,Dora Dias-Santagata,David T. Ting,Andrew X. Zhu,Theodore S. Hong,Todd R. Golub,Todd R. Golub,Todd R. Golub,A. John Iafrate,Viktor A. Adalsteinsson,Alberto Bardelli,Laxmi Parida,Dejan Juric,Gad Getz,Ryan B. Corcoran +48 more
TL;DR: Direct prospective comparison of circulating tumor DNA and tissue biopsy sequencing shows the superiority of liquid biopsies for capturing clinically relevant alterations mediating resistance to targeted therapies in cancer patients.
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha,Christine A. Parachoniak,Krishna S. Ghanta,Julien Fitamant,Kenneth N. Ross,Mortada S. Najem,Sushma Gurumurthy,Esra A. Akbay,Daniela Sia,Daniela Sia,Helena Cornella,Oriana Miltiadous,Chad Walesky,Vikram Deshpande,Andrew X. Zhu,Aram F. Hezel,Katharine E. Yen,Kimberly Straley,Jeremy Travins,Janeta Popovici-Muller,Camelia Gliser,Cristina R. Ferrone,Udayan Apte,Josep M. Llovet,Kwok-Kin Wong,Sridhar Ramaswamy,Sridhar Ramaswamy,Nabeel Bardeesy +27 more
TL;DR: It is shown that mutant IDH blocks liver progenitor cells from undergoing hepatocyte differentiation through the production of 2HG and suppression of HNF-4α, a master regulator of hepatocyte identity and quiescence, and presents a novel genetically engineered mouse model of IDH-driven malignancy.